124 related articles for article (PubMed ID: 757314)
1. Studies of the biochemical pharmacology of the fermentation-derived antitumor agent, (alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125).
Neil GL; Berger AE; Bhuyan BK; Blowers CL; Kuentzel SL
Adv Enzyme Regul; 1978; 17():375-98. PubMed ID: 757314
[No Abstract] [Full Text] [Related]
2. Biochemical and pharmacological effects of the fermentation-derived antitumor agent, (alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125).
Neil GL; Berger AE; McPartland RP; Grindey GB; Bloch A
Cancer Res; 1979 Mar; 39(3):852-6. PubMed ID: 427775
[No Abstract] [Full Text] [Related]
3. L-[alphaS, 5S]-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine.
Jayaram HN; Cooney DA; Ryan JA; Neil G; Dion RL; Bono VH
Cancer Chemother Rep; 1975; 59(3):481-91. PubMed ID: 1147
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Jayaram HN; Ardalan B; Deas M; Johnson RK
Cancer Res; 1985 Jan; 45(1):207-12. PubMed ID: 2578092
[TBL] [Abstract][Full Text] [Related]
5. The inhibition of gamma-glutamyl transpeptidase from human pancreatic carcinoma cells by (alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125; NSC-163501).
Allen L; Meck R; Yunis A
Res Commun Chem Pathol Pharmacol; 1980 Jan; 27(1):175-82. PubMed ID: 6102405
[TBL] [Abstract][Full Text] [Related]
6. A new antitumor agent, (alphas, 4s, 5r)-alpha-amino-3-chloro-4-hydroxy-4,5-dihydro-5-isoxazoleacetic acid (NSC-176324): preliminary evaluation against L 1210 mouse leukemia in vivo.
Martin DG; Hanka LJ; Neil GL
Cancer Chemother Rep; 1974; 58(6):935-7. PubMed ID: 4217217
[No Abstract] [Full Text] [Related]
7. Acivicin. An antitumor antibiotic.
Poster DS; Bruno S; Penta J; Neil GL; McGovren JP
Cancer Clin Trials; 1981; 4(3):327-30. PubMed ID: 7026076
[TBL] [Abstract][Full Text] [Related]
8. Enhanced effect of an L-glutamine antagonist, L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, by Acinetobacter L-glutaminase-L-asparaginase.
Holcenberg JS
Cancer Treat Rep; 1979 Jun; 63(6):1109-14. PubMed ID: 466650
[TBL] [Abstract][Full Text] [Related]
9. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of inactivation of glutamine amidotransferases by the antitumor drug L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125).
Tso JY; Bower SG; Zalkin H
J Biol Chem; 1980 Jul; 255(14):6734-8. PubMed ID: 6993476
[TBL] [Abstract][Full Text] [Related]
11. Biochemical mechanisms for the scheduled synergism of (alpha S, 5S)-2 amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid and 5-fluorouracil in P388 leukemia.
Ardalan B; Chandrasekaran B; Hrishikeshavan HJ
Cancer Chemother Pharmacol; 1985; 15(1):44-8. PubMed ID: 2408773
[TBL] [Abstract][Full Text] [Related]
12. A new antitumor antimetabolite, (alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): antimicrobial reversal studies and preliminary evaluation against L1210 mouse leukemia in vivo.
Hanka LJ; Martin DG; Neil GL
Cancer Chemother Rep; 1973 Apr; 57(2):141-8. PubMed ID: 4200486
[No Abstract] [Full Text] [Related]
13. The inhibition of gamma-glutamyl transpeptidase and glutathione metabolism of isolated rat kidney cells by L-(alpha S, 5S)-alpha-amino-3-chloro-4, 5-dihydro-5-isoxazoleacetic acid (AT-125; NSC-163501).
Reed DJ; Ellis WW; Meck RA
Biochem Biophys Res Commun; 1980 Jun; 94(4):1273-7. PubMed ID: 6104962
[No Abstract] [Full Text] [Related]
14. Monocytoid differentiation of freshly isolated human myeloid leukemia cells and HL-60 cells induced by the glutamine antagonist acivicin.
Nichols KE; Chitneni SR; Moore JO; Weinberg JB
Blood; 1989 Oct; 74(5):1728-37. PubMed ID: 2790198
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase.
Rosenfeld H; Roberts J
Cancer Res; 1981 Apr; 41(4):1324-8. PubMed ID: 7214322
[TBL] [Abstract][Full Text] [Related]
16. Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125.
Houchens DP; Ovejera AA; Sheridan MA; Johnson RK; Bogden AE; Neil GL
Cancer Treat Rep; 1979 Mar; 63(3):473-6. PubMed ID: 427827
[TBL] [Abstract][Full Text] [Related]
17. Biochemical pharmacology of acivicin in rat hepatoma cells.
Lui MS; Kizaki H; Weber G
Biochem Pharmacol; 1982 Nov; 31(21):3469-73. PubMed ID: 7150366
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cell cycle progression of human pancreatic carcinoma cells in vitro by L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, Acivicin (NSC 163501).
Meck RA; Clubb KJ; Allen LM; Yunis AA
Cancer Res; 1981 Nov; 41(11 Pt 1):4547-53. PubMed ID: 7306976
[TBL] [Abstract][Full Text] [Related]
19. Interaction of AT-125, (alpha S,5S)-amino-3-chloro-4,5-dihydroisoxazoleacetic acid, with bovine kidney gamma-glutamyl transpeptidase.
Allen LM; Corrigan MV; Meinking T
Chem Biol Interact; 1981 Jan; 33(2-3):361-5. PubMed ID: 6109574
[No Abstract] [Full Text] [Related]
20. Interaction of the antitumor drug, L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125) with renal brush border membranes. Specific labeling of gamma-glutamyl transpeptidase.
Kozak EM; Tate SS
FEBS Lett; 1980 Dec; 122(2):175-8. PubMed ID: 6110565
[No Abstract] [Full Text] [Related]
[Next] [New Search]
